Which has better earnings & valuation, CGON or HROW?

Harrow has higher revenue and earnings than CG Oncology. Harrow is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,582.80 -$160.99M -$2.33 N/A Harrow $272.30M 5.72 -$5.14M -$0.41 N/A

Is CGON or HROW more profitable?

CG Oncology has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Harrow -5.57% 19.59% 2.26%

Does the media favor CGON or HROW?

In the previous week, CG Oncology had 2 more articles in the media than Harrow. MarketBeat recorded 4 mentions for CG Oncology and 2 mentions for Harrow. CG Oncology's average media sentiment score of 0.96 beat Harrow's score of 0.94 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TWST or HROW more profitable?

Harrow has a net margin of -5.57% compared to Twist Bioscience's net margin of -19.85%. Harrow's return on equity of 19.59% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -19.85% -26.73% -19.15% Harrow -5.57% 19.59% 2.26%

Does the media favor TWST or HROW?

In the previous week, Twist Bioscience had 6 more articles in the media than Harrow. MarketBeat recorded 8 mentions for Twist Bioscience and 2 mentions for Harrow. Harrow's average media sentiment score of 0.94 beat Twist Bioscience's score of 0.52 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XENE or HROW?

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 2 mentions for Harrow. Xenon Pharmaceuticals' average media sentiment score of 1.47 beat Harrow's score of 0.94 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BLTE or HROW?

Harrow has higher revenue and earnings than Belite Bio. Harrow is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Harrow $272.30M 5.72 -$5.14M -$0.41 N/A

Is BLTE or HROW more profitable?

Belite Bio has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Harrow -5.57% 19.59% 2.26%

Does the media favor BLTE or HROW?

In the previous week, Belite Bio and Belite Bio both had 2 articles in the media. Harrow's average media sentiment score of 0.94 beat Belite Bio's score of 0.28 indicating that Harrow is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harrow (HROW) Competitors

$41.81 -0.67 (-1.58%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$40.95 -0.86 (-2.06%)

As of 07/13/2026 07:19 PM Eastern

Compare

HROW vs. CNTA, CGON, TWST, XENE, and BLTE

Should you buy Harrow stock or one of its competitors? MarketBeat compares Harrow with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harrow include Centessa Pharmaceuticals (CNTA), CG Oncology (CGON), Twist Bioscience (TWST), Xenon Pharmaceuticals (XENE), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Harrow compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Harrow (NASDAQ:HROW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Harrow has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Harrow	-5.57%	19.59%	2.26%

In the previous week, Harrow had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 2 mentions for Harrow and 0 mentions for Centessa Pharmaceuticals. Harrow's average media sentiment score of 0.94 beat Centessa Pharmaceuticals' score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

Company	Overall Sentiment
Centessa Pharmaceuticals	Neutral
Harrow	Positive

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Harrow has higher revenue and earnings than Centessa Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A
Harrow	$272.30M	5.72	-$5.14M	-$0.41	N/A

Centessa Pharmaceuticals presently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Harrow has a consensus target price of $69.43, indicating a potential upside of 66.06%. Given Harrow's stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Harrow beats Centessa Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Harrow compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

CG Oncology currently has a consensus price target of $81.73, indicating a potential upside of 12.73%. Harrow has a consensus price target of $69.43, indicating a potential upside of 66.06%. Given Harrow's higher probable upside, analysts plainly believe Harrow is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Harrow has higher revenue and earnings than CG Oncology. Harrow is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,582.80	-$160.99M	-$2.33	N/A
Harrow	$272.30M	5.72	-$5.14M	-$0.41	N/A

In the previous week, CG Oncology had 2 more articles in the media than Harrow. MarketBeat recorded 4 mentions for CG Oncology and 2 mentions for Harrow. CG Oncology's average media sentiment score of 0.96 beat Harrow's score of 0.94 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Harrow	-5.57%	19.59%	2.26%

CG Oncology has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Harrow has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Harrow beats CG Oncology on 9 of the 16 factors compared between the two stocks.

How does Harrow compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Harrow (NASDAQ:HROW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Twist Bioscience currently has a consensus price target of $84.30, indicating a potential downside of 6.70%. Harrow has a consensus price target of $69.43, indicating a potential upside of 66.06%. Given Harrow's higher probable upside, analysts clearly believe Harrow is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Twist Bioscience had 6 more articles in the media than Harrow. MarketBeat recorded 8 mentions for Twist Bioscience and 2 mentions for Harrow. Harrow's average media sentiment score of 0.94 beat Twist Bioscience's score of 0.52 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has a net margin of -5.57% compared to Twist Bioscience's net margin of -19.85%. Harrow's return on equity of 19.59% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Harrow	-5.57%	19.59%	2.26%

Twist Bioscience has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market. Comparatively, Harrow has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

72.8% of Harrow shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Harrow has lower revenue, but higher earnings than Twist Bioscience. Harrow is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	14.94	-$77.67M	-$1.33	N/A
Harrow	$272.30M	5.72	-$5.14M	-$0.41	N/A

Summary

Harrow beats Twist Bioscience on 9 of the 15 factors compared between the two stocks.

How does Harrow compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Harrow (NASDAQ:HROW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Harrow has higher revenue and earnings than Xenon Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	872.87	-$345.91M	-$4.70	N/A
Harrow	$272.30M	5.72	-$5.14M	-$0.41	N/A

Xenon Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Harrow has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Xenon Pharmaceuticals and 2 mentions for Harrow. Xenon Pharmaceuticals' average media sentiment score of 1.47 beat Harrow's score of 0.94 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 12.8% of Harrow shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Harrow	-5.57%	19.59%	2.26%

Xenon Pharmaceuticals currently has a consensus price target of $77.20, indicating a potential upside of 14.00%. Harrow has a consensus price target of $69.43, indicating a potential upside of 66.06%. Given Harrow's higher possible upside, analysts plainly believe Harrow is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Xenon Pharmaceuticals beats Harrow on 10 of the 17 factors compared between the two stocks.

How does Harrow compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Harrow (NASDAQ:HROW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Harrow has higher revenue and earnings than Belite Bio. Harrow is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Harrow	$272.30M	5.72	-$5.14M	-$0.41	N/A

Belite Bio presently has a consensus target price of $203.00, indicating a potential upside of 38.07%. Harrow has a consensus target price of $69.43, indicating a potential upside of 66.06%. Given Harrow's stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Belite Bio has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, Harrow has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

In the previous week, Belite Bio and Belite Bio both had 2 articles in the media. Harrow's average media sentiment score of 0.94 beat Belite Bio's score of 0.28 indicating that Harrow is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Harrow	-5.57%	19.59%	2.26%

Summary

Harrow beats Belite Bio on 11 of the 14 factors compared between the two stocks.

Get Harrow News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HROW vs. The Competition

Export

Metric	Harrow	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.58B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-101.97	19.17	27.11	24.26
Price / Sales	5.72	838.79	587.92	117.88
Price / Cash	49.15	56.80	29.22	49.36
Price / Book	29.65	4.22	10.75	6.29
Net Income	-$5.14M	$64.26M	$3.58B	$330.66M
7 Day Performance	-9.40%	-3.58%	-2.06%	-1.32%
1 Month Performance	11.08%	2.12%	3.32%	-0.64%
1 Year Performance	17.38%	20.35%	26.35%	19.08%

Harrow Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HROW Harrow	4.272 of 5 stars	$41.81 -1.6%	$69.43 +66.1%	+19.7%	$1.58B	$272.30M	N/A	180
CNTA Centessa Pharmaceuticals	0.8267 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200
CGON CG Oncology	2.8155 of 5 stars	$69.26 -1.6%	$81.73 +18.0%	+171.3%	$6.21B	$4.04M	N/A	61
TWST Twist Bioscience	1.7469 of 5 stars	$99.93 +0.7%	$84.30 -15.6%	+137.6%	$6.18B	$376.57M	N/A	990	Insider Trade
XENE Xenon Pharmaceuticals	2.6969 of 5 stars	$60.54 -0.7%	$77.20 +27.5%	+110.2%	$5.89B	$7.50M	N/A	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HROW) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow (HROW) Competitors

HROW vs. CNTA, CGON, TWST, XENE, and BLTE

How does Harrow compare to Centessa Pharmaceuticals?

Summary

How does Harrow compare to CG Oncology?

Summary

How does Harrow compare to Twist Bioscience?

Summary

How does Harrow compare to Xenon Pharmaceuticals?

Summary

How does Harrow compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harrow (HROW) Competitors

HROW vs. CNTA, CGON, TWST, XENE, and BLTE

How does Harrow compare to Centessa Pharmaceuticals?

Which has more risk and volatility, CNTA or HROW?

Is CNTA or HROW more profitable?

Does the media favor CNTA or HROW?

Do insiders & institutionals hold more shares of CNTA or HROW?

Which has stronger valuation and earnings, CNTA or HROW?

Do analysts prefer CNTA or HROW?

Summary

How does Harrow compare to CG Oncology?

Do analysts prefer CGON or HROW?

Which has better earnings & valuation, CGON or HROW?

Does the media favor CGON or HROW?

Is CGON or HROW more profitable?

Which has more volatility and risk, CGON or HROW?

Do institutionals and insiders hold more shares of CGON or HROW?

Summary

How does Harrow compare to Twist Bioscience?

Do analysts recommend TWST or HROW?

Does the media favor TWST or HROW?

Is TWST or HROW more profitable?

Which has more risk & volatility, TWST or HROW?

Do insiders & institutionals believe in TWST or HROW?

Which has higher valuation & earnings, TWST or HROW?

Summary

How does Harrow compare to Xenon Pharmaceuticals?

Which has stronger valuation & earnings, XENE or HROW?

Which has more risk & volatility, XENE or HROW?

Does the media prefer XENE or HROW?

Do institutionals & insiders believe in XENE or HROW?

Is XENE or HROW more profitable?

Do analysts rate XENE or HROW?

Summary

How does Harrow compare to Belite Bio?

Do institutionals and insiders believe in BLTE or HROW?

Which has better earnings and valuation, BLTE or HROW?

Do analysts rate BLTE or HROW?

Which has more risk and volatility, BLTE or HROW?

Does the media favor BLTE or HROW?

Is BLTE or HROW more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools